• Anlotinib Hydrochloride: Superior Multi-Target Angiogenesis

  2026-06-04

  This study demonstrates that anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor, effectively suppressing angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1. The findings highlight its superior efficacy compared to established anti-angiogenic agents, providing compelling evidence for its application in advanced cancer research.

• Romidepsin (FK228): Precision HDAC Inhibition in Spliceosome

  2026-06-04

  Explore how Romidepsin (FK228) enables advanced epigenetic modulation and spliceosome-targeted research in cancer biology. This article uniquely bridges HDAC inhibition, alternative splicing, and practical assay optimization, offering insights not found in standard Romidepsin protocols.

• GSK343 EZH2 Inhibitor: Protocol Advances for Epigenetic Canc

  2026-06-03

  GSK343 is a highly selective and cell-permeable EZH2 inhibitor, purpose-built for dissecting PRC2-mediated H3K27me3 in cancer epigenetics. This article translates emerging findings and real-world workflows into actionable guidance, maximizing the utility of GSK343 from APExBIO for robust, reproducible results in breast, prostate, and stem cell research.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-06-03

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, broadly sensitize diverse cancer cell lines to erastin-induced ferroptosis by promoting reactive oxygen species (ROS) accumulation and downregulating FSP1. These mechanistic insights clarify the role of BET inhibition in ferroptosis regulation and highlight actionable strategies for cancer research.

• Valemetostat (DS-3201): Protocols & Precision for EZH2 Mutan

  2026-06-02

  Valemetostat (DS-3201) is redefining epigenetic cancer therapy with its dual EZH1/EZH2 inhibition, offering unmatched selectivity and efficacy in relapsed/refractory lymphoma models. This article provides a stepwise guide to experimental workflows, advanced troubleshooting, and actionable insights for maximizing the compound’s translational impact in lymphoma research.

• Dual SMAD and Wnt Inhibition Enables Robust iPSC-RGC Differe

  2026-06-02

  This study presents a chemically defined protocol using dual SMAD and Wnt pathway inhibition to achieve efficient, reproducible differentiation of human iPSCs into retinal ganglion cells (RGCs) exceeding 80% purity. The approach addresses long-standing challenges in RGC modeling for glaucoma and neurodegenerative disease research, providing a foundation for more consistent disease modeling and therapeutic screening.

• EZH2 Inhibitors in HPV-Associated Cervical Cancer: Mechanist

  2026-06-01

  This study investigates the effects of EZH2 inhibitors, including EPZ-6438, on HPV-associated cervical cancer. It demonstrates that selective EZH2 blockade suppresses oncogenic HPV gene expression and promotes tumor suppressor pathways, offering a promising alternative to conventional chemotherapy.

• Nicotinamide Riboside Chloride (NIAGEN): Precision NAD+ Modu

  2026-06-01

  Unlock the latest advances in metabolic and neurodegenerative disease research with Nicotinamide Riboside Chloride (NIAGEN). Discover how precision NAD+ modulation supports robust retinal ganglion cell models and translational breakthroughs beyond standard methodologies.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-05-31

  This study presents a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation using small molecule pathway modulators. The innovation increases cellular diversity and proliferative capacity in organoids, enhancing their utility for disease modeling and high-throughput applications.

• GSK126 EZH2 Inhibitor: Transforming Cancer Epigenetics Resea

  2026-05-30

  GSK126, a potent EZH2 inhibitor from APExBIO, empowers researchers to dissect PRC2-driven gene silencing and tumor biology with unrivaled selectivity. This article delivers workflow-centric guidance, advanced troubleshooting tips, and bridges the latest mechanistic insights to practical applications in cancer epigenetics and beyond.

• JNJ-26481585 (Quisinostat): Targeted HDAC Inhibition in Canc

  2026-05-29

  JNJ-26481585 (Quisinostat) is a potent class I HDAC inhibitor with sub-nanomolar activity and demonstrated efficacy in apoptosis induction and tumor growth inhibition. It directly suppresses TRIM21, a key driver of drug resistance and cell proliferation in cancers, and offers reproducible results in diverse preclinical models. The compound's robust solubility in DMSO and validated anti-proliferative benchmarks make it a preferred HDAC inhibitor for research applications.

• Protease Inhibitor Cocktail (EDTA-Free, 200X): Practical Gui

  2026-05-29

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is formulated to prevent protein degradation during extraction and analysis workflows, especially when divalent cation-sensitive applications are involved. It is not suitable for studies requiring metalloprotease inhibition via chelation or workflows incompatible with DMSO.

• Tubastatin A: HDAC6 Inhibition for Precision Cell Death Cont

  2026-05-28

  Explore how Tubastatin A, a potent HDAC6 inhibitor, enables precise modulation of pyroptosis and necroptosis in translational research. This article uncovers advanced mechanistic insights and practical guidance distinct from routine summaries.

• Apigenin: Applied Protocols for Cancer and Neuroprotection R

  2026-05-28

  Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) enables precise modeling of HDAC inhibition and neuroprotective pathways. This guide translates network medicine insights and bench protocols into actionable workflows, with troubleshooting tips to maximize reproducibility in both oncology and Alzheimer’s disease research.

• LY2109761: TGF-β Receptor Type I and II Dual Inhibitor in Tu

  2026-05-27

  LY2109761 enables precise control of TGF-β signaling, supporting robust translational workflows in cancer and fibrosis models. Its selectivity and well-characterized inhibition profile facilitate both mechanistic studies and preclinical efficacy screens, with proven impact on radiosensitivity and tumor microenvironment modulation.

16712 records 1/1115 page Next 12345 下5页 Last page